FDA Inspection 1134720 — Zhejiang Guobang Pharmaceutical Co., Ltd
The FDA completed an inspection of Zhejiang Guobang Pharmaceutical Co., Ltd on Jan 10, 2020 in Shaoxing. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Jan 10, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Shaoxing (China)
Additional details
Mutual Recognition Agreement (MRA)